Thermo Fisher Scientific (TMO) shares ended the last trading session 8.2% higher at $453.55. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.5% loss over the past four weeks.Thermo Fisher scored a strong price increase, on investors’ optimism surrounding its impending 2025 first-quarter financial results, which is slated to release on April 23 before the opening bell. In the last reported quarter, the company ac ...

Thermo Fisher Scientific Inc.’s (TMO) recent slew of strategic acquisitions reflects its ongoing commitment to sustainable long-term growth. End markets play an important role as well, bolstering Thermo Fisher’s top line. Meanwhile, unfavorable foreign exchange and a fierce competitive landscape may create operational challenges for the company.In the past year, this Zacks Rank #3 (Hold) company’s shares have declined 15.5% compared with the industry’s 7.5% decline and the S&P 500 composite’s 8.3% rise.The ...

Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Biohazard Bags Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The global market for biohazard bags is anticipated to exhibit a robust compound annual growth rate (CAGR) of 5.04%, as it expands from a valuation of US$616.256 million in 2025 to US$787.964 million by the end of 2030. This growth trajectory is underpinned by the recognition of the critical need for stringent biomedical waste management in healthc ...

Thermo Fisher Scientific (TMO) has unveiled the Thermo Scientific Vulcan Automated Lab, a cutting-edge solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers.The latest development, which draws on decades of the company’s Electron Microscopy (EM) innovation, will likely bolster the Analytical Instruments segment.Predi ...

Core Insights - Thermo Fisher Scientific (NYSE: TMO) reported Q4'24 and FY'24 results that exceeded analyst and market expectations, indicating strong revenue and profitability growth despite the stock being rangebound for over a year [1] Financial Performance - The company has shown consistent revenue and profitability growth, which is a positive indicator for potential investors [1] Investment Perspective - The stock has been stable in price for over a year, suggesting a potential opportunity for investors looking for quality stocks in a solid business [1]

Group 1 - The life science industry showed modest improvement throughout 2024, with expectations for ongoing progress in 2025 [4] - Thermo Fisher Scientific posted strong fourth quarter earnings and provided positive financial guidance for 2025 [4] - The company indicated that 2023 was a challenging year for the industry, but they anticipated sequential market improvement in 2024 [5] Group 2 - The company expected the markets to be slightly down for the year but aimed to continue gaining market share [5] - The management highlighted the importance of understanding the evolving market backdrop and how it influenced their performance and strategy [5]

(Exact name of Registrant as specified in its charter) Delaware 04-2209186 (State of incorporation) (I.R.S. Employer Identification No.) 168 Third Avenue Waltham, Massachusetts 02451 (Address of principal executive of ices) (Zip Code) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Se ...

Core Insights - Thermo Fisher Scientific has launched the Invitrogen EVOS S1000 Spatial Imaging System, which enhances fluorescent microscopy by allowing researchers to create high-quality multiplexed images of multiple samples in a few hours, facilitating advancements in spatial tissue proteomics [1][5][6] Company Developments - The EVOS S1000 system is now commercially available in the United States and Europe, providing essential tools for researchers to better understand complex biological systems and develop new treatments for various diseases [2] - Following the announcement of the new system, TMO shares experienced a decline of 1.3%, closing at $538, although the company continues to benefit from past innovations and the introduction of impactful new products [3] - Thermo Fisher has a market capitalization of $208.55 billion, with a Zacks Consensus Estimate predicting a 2.4% increase in both earnings and revenues year-over-year [4] Product Significance - The EVOS S1000 utilizes advanced spectral technology to capture images of up to 9 different targets simultaneously, reducing the need for multiple imaging rounds and preserving tissue integrity, which is crucial for developing treatments for solid tumors and neurodegenerative diseases [5][6] - The system provides detailed insights into tissue microenvironments and architecture, enabling researchers to accelerate experiments and enhance their research capabilities [6] Industry Outlook - The Spatial Proteomics market is projected to grow from $92.4 million in 2024 at a compound annual growth rate of 12.7% through 2030, driven by advancements in imaging techniques, mass spectrometry, and artificial intelligence [7]

Investment Rating - The report maintains a "BUY" rating for Thermo Fisher, with a target price raised from US$670 to US$690, indicating an upside potential of 18.5% from the current price of US$582.38 [3][7]. Core Insights - Thermo Fisher delivered a strong performance in 4Q24, with revenue growth of 4.7% YoY and adjusted EPS growth of 7.6%, surpassing consensus estimates [1][7]. - The company anticipates revenue growth of 1.4-2.6% YoY and adjusted EPS growth of 5.7-7.5% YoY for 2025, reflecting a positive outlook [1][7]. - A robust demand outlook is expected to continue, driven by pharmaceutical innovation and a favorable biotech funding environment, with management projecting long-term industry growth of 4-6% and organic growth for Thermo Fisher of 7-9% [7][8]. - The company plans to invest US$1.4-1.7 billion in capital expenditures in 2025, marking an 11% YoY increase, the first such growth since 2021 [7]. Financial Summary - For FY24, Thermo Fisher reported revenue of US$42,879 million, with a slight YoY growth of 0.1%. The forecast for FY25 is US$44,129 million, representing a growth of 2.9% YoY [2][15]. - Adjusted net profit for FY24 was US$8,380 million, with an expected increase to US$8,852 million in FY25, reflecting a growth of 5.6% YoY [2][15]. - The adjusted EPS for FY24 was US$21.94, projected to rise to US$23.38 in FY25, indicating a growth of 6.6% [2][15]. Segment Performance - In 4Q24, all business segments showed sequential improvements, with Life Science growing by 5.5% YoY, Analytical Instruments by 7.3% YoY, and Laboratory Products and Biopharma Services by 3.8% YoY [7][8]. - The clinical CRO business experienced low single-digit growth in 2024, while the demand from China showed signs of recovery, with low single-digit growth in revenue [7][8]. Market Position - Thermo Fisher's market capitalization stands at approximately US$222.47 billion, with significant institutional ownership from Vanguard (8.6%) and BlackRock (7.6%) [3][4]. - The stock has shown a 1-month performance of 8.4% and a 3-month performance of 4.1%, indicating positive market sentiment [5][6].

Core Insights - The article emphasizes that past performance does not guarantee future results, using Thermo Fisher Scientific (NYSE: TMO) as a case study [1][3] - The author has a long position in TMO shares, indicating a belief in the company's potential for future growth [2] Company Analysis - Thermo Fisher Scientific is highlighted as a stock that has shown strong historical performance, but the article cautions that this may not be indicative of future results [1] - The author focuses on long-term investment strategies, suggesting that TMO may be a suitable candidate for investors looking to maximize total returns over time [1] Investment Strategy - The investment approach discussed involves buying stocks when their prices are low relative to their intrinsic value, which could apply to TMO if it presents such an opportunity [1] - The author prefers to hold positions for the long term unless there is a compelling reason to sell, which aligns with a conservative investment philosophy [1]